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Chapter 11
Vitamin B-6 Metabolism and Interactions
with TNAP
Stephen P. Coburn
Abstract Two observations stimulated the interest in vitamin B-6 and alkaline
phosphatase in brain: the marked increase in plasma pyridoxal phosphate and the
occurrence of pyridoxine responsive seizures in hypophosphatasia. The increase in
plasma pyridoxal phosphate indicates the importance of tissue non-speciﬁc alkaline
phosphatase (TNAP) in transferring vitamin B-6 into the tissues. Vitamin B-6 is
involved in the biosynthesis of most of the neurotransmitters. Decreased
gamma-aminobutyrate (GABA) appears to be most directly related to the devel-
opment of seizures in vitamin B-6 deﬁciency. Cytosolic pyridoxal
phosphatase/chronophin may interact with vitamin B-6 metabolism and neuronal
development and function. Ethanolaminephosphate phospholyase interacts with
phosphoethanolamine metabolism. Extracellular pyridoxal phosphate may interact
with purinoceptors and calcium channels. In conclusion, TNAP clearly influences
extracellular and intracellular metabolism of vitamin B-6 in brain, particularly
during developmental stages. While effects on GABA metabolism appear to be the
major contributor to seizures, multiple other intra- and extra-cellular metabolic
systems may be affected directly and/or indirectly by altered vitamin B-6 hydrolysis
and uptake resulting from variations in alkaline phosphatase activity.
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11.1 Introduction to Vitamin B-6 Compounds
and Metabolism
Studies of the interaction between vitamin B-6 and alkaline phosphatase have been
reported for many years. One of the reasons for exploring vitamin B-6 metabolism
in the current volume was the occurrence of pyridoxine responsive seizures in
hypophosphatasia, a rare genetic disorder which inactivates tissue non-speciﬁc
alkaline phosphatase (TNAP) (See Chaps. 1, 2, 3 and 14). Several reports suggest
that Bethenod et al. (1967) reported pyridoxine responsive seizures in hypophos-
phatasia in 1967. This appears to be an error. Bethenod et al. did administer
pyridoxine but it was not effective in relieving the seizures. Since then there have
been multiple reports in which vitamin B-6 supplementation was beneﬁcial (Sia
et al. 1975; Litmanovitz et al. 2002; Nunes et al. 2002; Yamamoto et al. 2004; Arun
et al. 2005; Baumgartner-Sigl et al. 2007; Balasubramaniam et al. 2010; Demirbilek
et al. 2012; Belachew et al. 2013). Vitamin B-6 supplementation also corrected
seizures in mice lacking alkaline phosphatase (Waymire et al. 1995; Narisawa et al.
2001). Finally, pyridoxal phosphate concentrations in plasma are markedly elevated
in hypophosphatasia (Whyte et al. 1985) demonstrating an important physiological
role for alkaline phosphatase in vitamin B-6 metabolism.
Vitamin B-6 is the name for a group of compounds with similar biological
activity. The major forms in humans are pyridoxine, pyridoxal, pyridoxamine, their
corresponding 5′-phosphate derivatives and the metabolic end product, 4-pyridoxic
acid (Table 11.1; Fig. 11.1). Additional metabolites have been detected in humans
receiving megadoses of vitamin B-6 (Mahuren et al. 1991) as well as in cats
(Coburn and Mahuren 1987) and dogs (Ericson et al. 2008). The interconversion of
the various forms combined with the wide variety of reactions in which vitamin B-6
is utilized makes detailed study challenging. Pyridoxal phosphate is a cofactor for
over 150 enzymes representing every major class of enzymes except ligases (http://
enzyme.expasy.org). This accounts for about 4 % of known enzyme activity
(Percudani and Peracchi 2003). These enzymes catalyze reactions including
transamination, decarboxylation, racemization, aldol cleavage, and beta and gamma
eliminations and replacement reactions leading Jansonius (1998) to conclude that
pyridoxal phosphate is the most versatile organic catalyst known. It has been
suggested that the most ancient reaction of aerobic metabolism was the synthesis of
pyridoxal phosphate or pyridoxal (Kim et al. 2012). Much information about the
structure, sequence and function of vitamin B-6 enzymes is contained in the vitamin
B-6 database (http://bioinformatics.unipr.it/cgi-bin/bioinformatics/B6db/home.pl)
(Percudani and Peracchi 2009). Although reactions involving amino acid metabo-
lism seem to attract the most attention, 70–80 % of the vitamin B-6 in mammals is
located in skeletal muscle (Coburn et al. 1988a) associated with glycogen phos-
phorylase where the phosphate group rather than the amine or aldehyde group is the
catalytic center (Palm et al. 1990). Also, while many studies of vitamin B-6 focus
on pyridoxal phosphate, in most tissues other than muscle the amount of pyridoxal
phosphate is equaled or exceeded by the amount of pyridoxamine phosphate
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(Coburn et al. 1988b). There is little information on the rate of interchange of these
forms. Unless enzymatic activity is inhibited during homogenization, pyridoxamine
phosphate in liver is quickly converted to pyridoxal phosphate (Coburn et al.
1988b). That suggests that the two compounds may be sequestered separately. It
also raises questions about the accuracy of observed vitamer distribution in some
studies. The commonly accepted pathway of vitamin B-6 metabolism in humans
(Fig. 11.1) involves phosphorylation of the 5′-position by pyridoxal kinase (EC 3.7.
1.35). The kinase can phosphorylate all three vitamers. Pyridoxine phosphate and
pyridoxamine phosphate may be oxidized to pyridoxal phosphate. The oxidizing
enzyme is usually named pyridoxine (pyridoxamine) phosphate oxidase. However,
the name recommended by the Enzyme Commission is pyridoxal 5′-phosphate
synthase (EC 1.4.3.5). The synthase can oxidize both pyridoxine phosphate and
pyridoxamine phosphate. It is inhibited by its substrate, pyridoxine phosphate
(Ki = 60 μΜ) (Kwon et al. 1991) and product, pyridoxal phosphate (Ki = 23 μΜ)
(Kwok and Churchich 1980). Pyridoxal 5′-phosphate synthase activity varies
considerably between tissues and between species (Fonda 1988). Mouse and human
erythrocytes have appreciably higher activity than rat, hamster and rabbit erythro-
cytes. This means that the role of erythrocytes in vitamin B-6 metabolism will vary
signiﬁcantly between species. Pyridoxamine phosphate and pyridoxal phosphate
can also be interconverted by aminotransferases. The phosphate group can be
Table 11.1 Vitamin B-6 compounds and major enzymes associated with the interconversion of
B-6 vitamers in animals
Vitamin B-6 metabolites Abbreviation CAS Registry No.
Pyridoxine PN 65-23-6
Pyridoxal PL 66-72-8
Pyridoxamine PM 85-87-0
Pyridoxine 5′-phosphate PNP 447-05-2
Pyridoxal 5′-phosphate PLP 54-47-7
Pyridoxamine 5′-phosphate PMP 529-96-4
4-pyridoxic acid PA 82-82-6
Enzymes Enzyme commision No. CAS registry No.
Pyridoxal kinase (1)a 2.7.1.35 9025-42-0
Pyridoxal phosphatase (2) 3.1.3.74 9076-92-0
Alkaline phosphatase (2) 3.1.3.1 9001-78-9
Pyridoxal 5′-phosphate synthase (3) 1.4.3.5 9055-72-5
Multiple aminotransferases (4) 2.6.1 –
Aldehyde oxidase (5) 1.2.3.1 9029-07-6
Aldehyde dehydrogenase (NAD+) (6) 1.2.1.3 9028-86-8
Aldehyde dehydrogenase (NADP+) (6) 1.2.1.4 9028-87-9
Aldehyde dehydrogenase (NAD(P)+) (6) 1.2.1.5 9028-88-0
aNumber in parentheses indicates the associated reaction in Fig. 11.1. In some cases the enzyme
involved may vary depending on the species, tissue and cellular locations. Enzymes which have
been identiﬁed only in microorganisms are not listed
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removed by non-speciﬁc phosphatases or by pyridoxal phosphatase (EC 3.1.3.74).
Pyridoxal can be oxidized to 4-pyridoxic acid by aldehyde oxidase (EC 1.2.3.1)
which has been detected in a variety of tissues (Moriwaki et al. 2001). Stanulovic
et al. (1976) found that rats lacking aldehyde oxidase were able to produce pyri-
doxic acid using a NAD dependent aldehyde dehydrogenase. The identity of this
dehydrogenase remains unclear. Although Stanulovic et al. (1976) suggested that it
is probably the nonspeciﬁc aldehyde dehydrogenase EC 1.2.1.3, the Enzyme
Nomenclature database (http://www.chem.qmul.ac.uk/iubmb/enzyme/index.html)
lists three nonspeciﬁc aldehyde dehydrogenases (EC 1.2.1.3 using NAD, EC 1.2.1.
4 using NADP and EC 1.2.1.5 using both) plus pyridoxal dehydrogenase (EC 1.1.1.
107) described in bacteria (Burg and Snell 1969). Although Stanulovic et al. (1976)
used NAD, Bode et al. (1991) detected pyridoxal dehydrogenase activity in rats
using NADP which they assigned to EC 1.2.1.4. Chemical Abstracts assigned the
Stanulovic rat enzyme the same CAS number as the bacterial enzyme. However,
there is no obvious justiﬁcation for that. Pyridoxal dehydrogenase activity was not
detected in human liver using NAD or NADP (Merrill et al. 1984). Therefore, it
seems unlikely to occur in human brain.
Fig. 11.1 Major pathways of vitamin B-6 metabolism. The enzymes associated with the reactions
are listed in Table 11.1
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11.2 Absorption and Transport of Vitamin B-6
Intestinal absorption of unphosphorylated vitamin B-6 appears to involve diffusion
and/or facilitated diffusion (Mooney et al. 2009). While it is frequently assumed that
the ionic nature of pyridoxal phosphate prevents it from crossing cell membranes
without prior hydrolysis, perfusion studies in rats demonstrated that pyridoxal
phosphate can be transferred intact from the lumen of the intestine into the circu-
lation (Mehansho et al. 1979). Although liver is a major site of vitamin B-6
metabolism, small doses of pyridoxine and pyridoxamine can be converted to
pyridoxal in the intestine prior to release into the portal circulation in the mouse
(Sakurai et al. 1987, 1988). Similar results were reported with cultured Caco-2 cells
(Albersen et al. 2013). The main transport forms of vitamin B-6 in blood are
pyridoxal and pyridoxal phosphate, which is released from the liver associated
primarily with albumin (Lumeng et al. 1974). Hydrolysis by TNAP is important in
removal of pyridoxal phosphate from plasma as indicated by a marked increase in
plasma concentrations of pyridoxal phosphate when TNAP activity is limited in
hypophosphatasia (Whyte et al. 1985). Signiﬁcant amounts of pyridoxine and
pyridoxamine do not occur in peripheral plasma with normal vitamin B-6 intake
(Albersen et al. 2014). Therefore, intravenous administration of pyridoxine pro-
duces atypical metabolism. For example, skeletal muscle in mice and rats contains
pyridoxal kinase but little, if any, pyridoxal 5′-phosphate synthase (Fonda 1988).
Therefore, pyridoxine can be taken up by muscle and phosphorylated but cannot be
converted to pyridoxal phosphate. It must be hydrolyzed and released back into the
circulation. This is not necessarily harmful but it does not reflect the normal kinetic
processes followed by pyridoxal and pyridoxal phosphate.
Early attempts to isolate phosphatases produced variable results. Saraswathi and
Bachhawat (1963) isolated from human brain an alkaline phosphatase for which
pyridoxal phosphate was the best substrate with a Km of 0.430 mM at pH 9.
Magnesium was required for optimal activity. Inorganic phosphate was a com-
petitive inhibitor with Ki of 1.65 mM. Brunel et al. (1969) and Zisapel and Levi
(1980) independently isolated from bovine brain alkaline phosphatases which had
little activity toward pyridoxal phosphate. Brun-Heath et al. (2011) recently dem-
onstrated that the alkaline phosphatase expressed in human neuronal and endo-
thelial cells corresponds to the ALPL gene driven by the bone promoter. The
interactions between alkaline phosphatase, pyridoxal phosphate, pH and inorganic
phosphate are complex. Examination of the membrane bound alkaline phosphatase
of rat liver demonstrated that at pH 7.4 the Km for pyridoxal phosphate was about
2 µM, which is approximately the concentration of free pyridoxal phosphate in liver
(Lumeng and Li 1975). The enzyme was very sensitive to substrate inhibition by
pyridoxal phosphate but not by p-nitrophenyl phosphate. Inorganic phosphate is a
well-recognized inhibitor of alkaline phosphatase. Under physiological conditions
alkaline phosphatase activity toward pyridoxine phosphate was reduced about 50 %
by normal plasma phosphate concentrations and will increase or decrease signiﬁ-
cantly in response to changes in phosphate concentrations within the ranges
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observed clinically (Coburn et al. 1998). The measurements utilized pyridoxine
phosphate rather than pyridoxal phosphate in order to minimize substrate inhibition
and non-speciﬁc protein binding. The article includes a nomogram for predicting
pyridoxine phosphate phosphatase activity in undiluted serum from routine clinical
measurements of inorganic phosphate and alkaline phosphatase. Seargeant and
Stinson (1979) estimated that inorganic phosphate concentrations in liver would be
high enough to inhibit human liver alkaline phosphatase if the phosphate was
accessible to the enzyme.
Spector and Johanson (2007) noted that there are ﬁve general processes that
must be understood to explain mechanistically vitamin homeostasis in brain:
(i) Transport from plasma in and out of the extracellular space of brain and
cerebrospinal fluid;
(ii) Uptake and release of transported vitamers by brain cells;
(iii) Vitamer activation by kinases or other enzymes, i.e. incorporation into
cofactors and transfer into appropriate compartments in the brain cells;
(iv) When appropriate, reformation of the transported vitamer for release from the
brain cell and then the central nervous system; and
(v) Finally, mechanisms in kidney and gut including saturable uptake, excretion,
and secretion (kidney) mechanisms that tend to keep plasma vitamin levels
constant, thus contributing to brain homeostasis.
Uptake by the choroid plexus primarily involves diffusion or facilitated diffusion
of non-phosphorylated vitamers followed by trapping by pyridoxal kinase (Spector
and Greenwald 1978). Dual label experiments with [3H, 32P]pyridoxine phosphate
indicated that only 10–15 % of the absorbed vitamer was absorbed without
hydrolysis. Since TNAP is expressed at high levels in the choroid plexus (Nishihara
et al. 1994), reduced activity in hypophosphatasia could signiﬁcantly impair vita-
min B-6 uptake. During a 30 min period 56 % of accumulated [3H] was released
from isolated choroid plexus and 46 % from brain slices (Spector 1978b). However,
76 % of the label released by choroid plexus was phosphorylated compared to 1 %
from brain slices. Therefore, choroid plexus accounts for essentially all of the
phosphorylated B-6 vitamers in the cerebrospinal fluid (CSF). The rabbit choroid
plexus can also absorb unphosphorylated vitamers from the CSF. Since the non-
phosphorylated vitamers are removed from the CSF faster than pyridoxal phos-
phate, Spector and Johanson (2007) suggested that the phosphorylated form serves
as a reservoir. [3H]pyridoxic acid or [3H]pyridoxic acid lactone accounted for less
than 10 % of the label in plasma or CSF from in vivo experiments (Spector 1978a)
and less than 5 % of the label released from brain and choroid plexus slices from
in vitro experiments (Spector 1978b). Spector and Johanson (2007) gave the fol-
lowing data from rabbits: total vitamin B-6 in plasma is 0.30 µmol/L 55 % non-
phosphorylated; 0.39 µmol/L in cisternal CSF 26 % nonphosphorylated;
8.9 µmol/kg in brain 23 % nonphosphorylated; brain turnover 17 %/d; CSF turn-
over 24 %/3 h; permeability-surface area product <10 compared to 0.2 for mannitol
(absorbed by simple diffusion) and 158 for leucine (absorbed by facilitated diffu-
sion); Kt * 1–2 µmol/L (half saturation concentration for transport through the
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blood brain barrier). Spector and Johanson (2007) concluded that since the Kt is
similar to plasma concentration the carrier mediated process plays a crucial trans-
port and regulatory role because simple diffusion is relatively unimportant.
In human cerebrospinal fluid pyridoxal is the dominant B-6 vitamer (Albersen
et al. 2012; van der Ham et al. 2012; Albersen et al. 2014). Median values for
pyridoxal and pyridoxal phosphate in the cerebrospinal fluid of infants declined
over 50 % between a postmenstrual age of 30–37 and ≥42 weeks (Albersen et al.
2012). Two studies which measured only pyridoxal phosphate found that the
decline continued for at least 12 months after birth (Ormazabal et al. 2008; Footitt
et al. 2011). In adult subjects the median values for pyridoxal and pyridoxal
phosphate were 10.5 and 55.9 nmol/L in plasma and 30.0 and 16.1 nmol/L in
cerebrospinal fluid, respectively (Albersen et al. 2014). They reported a correlation
of 0.629 between pyridoxal phosphate in cerebrospinal fluid and plasma. This
might be interpreted to indicate direct transport of pyridoxal phosphate from plasma
to cerebrospinal fluid. However, an alternative explanation could be that hydrolysis
of pyridoxal phosphate in plasma is the primary source of the pyridoxal used to
synthesize the pyridoxal phosphate released into the cerebrospinal fluid by the
choroid plexus.
11.3 Vitamin B-6 Transporters
Evidence that vitamin B-6 uptake may involve facilitated diffusion implies the
existence of transporters. A vitamin B-6 transporter has been identiﬁed in S. cer-
visiae (Stolz and Vielreicher 2003). The Tpn1p protein is a member of the
purine-cytosine permease family within the major facilitator superfamily and
functions as a proton symporter in the plasma membrane. In S. pombe the pyri-
doxine transporter was a different proton symporter encoded by the car1+ (changed
amyloride resistance) gene which Stolz et al. (2005) proposed renaming bsu1+ for
vitamin B-6 uptake. Carrier mediated pyridoxine transport sensitive to amiloride
has been reported in Caco-2 cells (Said et al. 2003; Stolz et al. 2005). However,
Stolz et al. (2005) stated that no mammalian homologue of Bsu1p has been iden-
tiﬁed in database searches and Said (2011) acknowledges that nothing is known
about the molecular structure of the intestinal pyridoxine transporter of any
mammalian species. It has recently been proposed that the transporter could be used
to enhance transfection of cancer cells by attaching a ligand to pyridoxal phosphate
(Pandey et al. 2013). The hypothesis is that the pyridoxal phosphate will bind to the
transporter but the large size will prevent transport resulting in endocytosis of the
entire complex. This protocol did express luciferase in mouse brain suggesting that
a vitamin B-6 transporter does act in brain.
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11.4 Intracellular Pyridoxal Phosphatase (EC 3.1.3.74)
TNAP is a membrane bound ectoenzyme which has a major role in controlling
extracellular pyridoxal phosphate concentrations. In rat neurons pyridoxal phos-
phatase activity at pH 5.0 was cytochemically located in a specialized region of
smooth endoplasmic reticulum that is located at the trans face of the stack of Golgi
elements (GERL) (Spater et al. 1978). These locations differed from the usual sites
of both acid and alkaline phosphatase activity. In 1992 Fonda (1992) observed that
human erythrocytes contained alkaline phosphatase activity associated with the
stroma and a soluble acid phosphatase which hydrolyzed vitamin B-6 phosphates.
The optimal pH was 6.5. At pH 7.4 it hydrolyzed vitamin B-6 phosphates but not
nucleotide phosphates, phosphoamino acids or other phosphorylated compounds.
At pH 7.4 the Km was 1.5 µM. Activity was inhibited by inorganic phosphate
(Ki = 0.8 mM), fluoride and weakly by pyridoxal. It was not inhibited by levam-
isole, L-phenylalanine or L-tartrate. Based on tryptic fragments obtained by Gao
and Fonda (1994), Jang et al. (2003) were able to identify the pyridoxal phos-
phatase in a cDNA library from human brain and express it in E. coli. The mouse
enzyme was also cloned. BLAST searches identiﬁed similar proteins in organisms
ranging from bacteria to mammals. The enzyme is a dimer requiring magnesium for
optimal activity. The Km values for the human enzyme were 2.5, 43.4 and 80.6 for
pyridoxal phosphate, pyridoxine phosphate and pyridoxamine phosphate, respec-
tively. There was little activity with p-nitrophenylphosphate. Phosphatase mRNA
was detected in essentially all tissues tested but was highest in adult and fetal brain.
Liver and testis were higher than tissues other than brain. Expression in spinal cord
was much lower than in brain. The structure shows no evidence of integral mem-
brane domains which is consistent with the erythrocyte enzyme being found in the
soluble fraction. Based on these data in 2004 the Enzyme Commission created EC
3.1.3.74, pyridoxal phosphatase, which has the systematic name, pyridoxal 5′-
phosphate phosphohydrolase.
Kang et al. (2004) examined the relative mRNA expression of pyridoxal 5′-
phosphate synthase (PNPO), pyridoxal kinase (PDXK) and pyridoxal phosphatase
(PDXP) in a wide variety of human tissues which are partially listed in Table 11.2.
Maximal expression of the synthase, kinase and phosphatase was in the liver, testis
and cerebral cortex, respectively. Expression of pyridoxal phosphatase mRNA in
most brain regions was greater than 80 % of the maximum while expression of
oxidase and kinase mRNA was below 35 % of the maximum. Boe et al. (2004)
identiﬁed autoantigens to pyridoxal phosphatase in patients with paraneoplastic
neurologic disorders. They conﬁrmed that the pyridoxal phosphatase gene, PDXP,
was most strongly expressed in various regions of the brain. Expression was also
signiﬁcant in liver, kidney and testis.
Gohla et al. (2005) found that pyridoxal phosphatase also activates coﬁlin, a key
regulator of cytoskeletal dynamics. They named the pyridoxal phosphatase protein,
chronophin. Lack of this enzyme causes major cell division defects. Northern blot
analysis revealed high expression in brain, heart, skeletal muscle, liver and kidney.
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Kim et al. (2008) found that pyridoxal phosphatase/chronophin was localized pri-
marily in postsynaptic compartments and not in presynaptic compartments in rat
hippocampus. They concluded that the interaction of pyridoxal
phosphatase/chronophin with actin may have an important role in seizure activity.
Hwang et al. (2007) examined the effect of ischemia produced by 5 min occlusion
of the carotid arteries on vitamin B-6 metabolizing enzymes in the gerbil hippo-
campus. Ischemia had no signiﬁcant effect on the amount of pyridoxal 5′-phosphate
synthase in the CA2/3 regions. In the CA1 region relative optical density of the
pyridoxal 5′-phosphate synthase spot vs sham was highest 12 h after ischemia,
declined slightly until 2 days and returned to baseline by 4 days. Relative optical
density of the pyridoxal phosphatase spot declined about 50 % at 3 h and peaked at
about twice the sham spot after 2 days. Administration of pyridoxal phosphate
30 min prior to the ischemic event minimized the loss of pyramidal cells 4 days
later. Hwang et al. suggested that this protective effect may have resulted from
increased GABA. Koh (2010) examined the response of rats to middle cerebral
Table 11.2 Relative mRNA
expression of pyridoxine
phosphate oxidase (PNPO),
pyridoxal kinase (PDXK) and
pyridoxal phosphatase
(PDXP) in human tissues
(Kang et al. 2004)
Tissue PNPO PDXK PDXP
Whole brain 23.8 29.0 83.6
Cerebral cortex 25.9 27.0 100.0
Frontal lobe 12.4 14.3 81.8
Parietal lobe 13.6 32.2 82.4
Occipital lobe 14.7 25.3 89.1
Temporal lobe 12.6 24.4 84.6
Paracentral gyrus of cerebral
cortex
9.5 18.5 73.2
Pons 6.2 10.3 47.9
Cerebellum, left 13.3 21.9 90.5
Cerebellum, right 25.0 31.1 91.1
Corpus callosum 18.4 19.8 37.7
Amygdala 13.0 22.6 94.2
Caudate nucleus 19.2 28.4 74.2
Hippocampus 12.3 24.6 81.8
Medulla oblongata 5.0 15.8 41.7
Putamen 2.0 17.9 54.2
Accumbens nucleus 5.2 19.4 70.8
Thalamus 10.8 23.1 85.2
Spinal cord 1.6 3.7 10.8
Heart 3.7 9.1 18.7
Kidney 85.6 58.0 31.4
Skeletal muscle 34.1 15.4 20.7
Testis 8.4 100.0 49.3
Liver 100.0 56.0 61.8
Highest expressing tissue for each enzyme was set to 100
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artery occlusion for 24 h. The pyridoxal phosphatase spot from the cerebral cortex
was signiﬁcantly reduced at 18 % of the sham group. Koh did not cite the earlier
results from Hwang et al. The difference in the response of pyridoxal phosphatase
could reflect the difference in duration of ischemia and/or the portion of the brain
examined. Furukawa et al. (2010) found that pyridoxal phosphatase activity was
increased in the limbic forebrain of 3 month old senescence-accelerated mouse
prone 10 (SAMP10) and suggested that morphological impairments in cytoplasmic
processes of microglia may be related to the altered expression of pyridoxal
phosphatase since this enzyme is known to be involved in brain cytoskeleton
formation and associated with acute and chronic neurodegenerative conditions.
Pyridoxal phosphatase/chronophin dephosphorylates pyridoxal phosphate and
actin-depolymerizing factor giving it a role in regulating both vitamin B-6 and
F-actin (Kim et al. 2009). Kim et al. (2009) concluded that pyridoxal
phosphatase/chronophin mediated actin dynamics may play an important role in the
changes of morphological properties (dendritic spine reorganization) of the hip-
pocampus in long-term potentiation. (Kim et al. 2008; Kwak et al. 2009).
11.5 Regulation of Vitamin B-6 Metabolism
Determining how vitamin B-6 metabolism is regulated is challenging. While it is
frequently assumed that water soluble vitamins are readily lost from the body,
vitamin B-6 seems to be efﬁciently conserved by most tissues. Pyridoxal kinase
complexes with aspartate aminotransferase resulting in channeling newly formed
pyridoxal phosphate to the aminotransferase (Kim et al. 1988). During vitamin B-6
deﬁciency in rats the large pool of pyridoxal phosphate sequestered in muscle
glycogen phosphorylase was not released until anorexia and weight loss occurred
(Black et al. 1978). When young adult men were placed on a controlled diet
providing about 0.5 mg vitamin B-6/d, within 2 weeks their urinary excretion had
dropped to approximate their intake with a loss of only 4 % of their body pool
(Coburn et al. 1991). While plasma content dropped markedly, muscle content
showed little change after 6 weeks. If the body conserves vitamin B-6, we
hypothesized that the vitamin B-6 requirement for growth could be determined by
multiplying the daily gain by the average body content of vitamin B-6 (15 nmol/g)
(Coburn 1994). This approach provided reasonable agreement with experimentally
determined requirements for species ranging from mammals to birds and ﬁsh. The
total body pool in humans is about 1,000 µmol (Coburn et al. 1988a). We proposed
that the turnover is determined primarily by vitamin B-6 intake. As noted below at
very low intakes brain is adversely affected. If existing tissue efﬁciently conserves
vitamin B-6, the fact that most studies of vitamin B-6 metabolism involve growing
rats raises the possibility that the observed reductions in tissue vitamers are mag-
niﬁed by the addition of new tissue and do not necessarily represent changes that
would occur in an animal maintaining a constant weight.
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Rats receiving vitamin B-6 intakes ranging from 2 to 200 times the daily
requirement for 20 days showed no signiﬁcant difference in the pyridoxal phosphate
content of liver or brain indicating that maximal pyridoxal phosphate content is well
regulated (Li et al. 1974). Since pyridoxal 5′-phosphate synthase from liver (Wada
and Snell 1961; Merrill et al. 1984) or brain (Kwok and Churchich 1980) is very
sensitive to product inhibition by pyridoxal phosphate, the synthase was proposed
as a regulatory factor (Snell and Haskell 1971; Merrill et al. 1978). Therefore, Li
et al. (1974) tested the effect of pyridoxal phosphate on pyridoxal phosphate pro-
duction by rat liver cytosol in vitro. They concluded there was no effect because the
total produced was similar with and without added pyridoxal phosphate. However,
Merrill et al. (1978) noted that the data of Li et al. did show a slightly decreased rate
of production with added pyridoxal phosphate indicating that there was inhibition.
Li et al. observed that adding 80 mM sodium phosphate to inhibit phosphatase
activity resulted in a marked increase in net pyridoxal phosphate production in
hepatocytes or plasma membranes but not cytosol. Therefore, Li et al. concluded
that under normal circumstances pyridoxal phosphate which is not protected by
protein binding is rapidly hydrolyzed thus maintaining a steady state. Since the
phosphatase activity was in the membrane fraction but not the cytosol, it presum-
ably represented alkaline phosphatase rather than pyridoxal phosphatase. We now
know that alkaline phosphatase is an ectoenzyme. One explanation of the results of
Li et al. might be that the pyridoxal phosphate produced by the hepatocytes was
released into the medium before being hydrolyzed. The description of the sample
processing does not indicate that the hepatocytes were separated from the medium
before pyridoxal phosphate analysis. Liver routinely releases pyridoxal phosphate
into the plasma (Lumeng et al. 1974) but brain may not (Spector 1978b). Perhaps in
brain pyridoxal phosphatase controls the intracellular pyridoxal phosphate
concentration.
Ohkawa et al. (1994) used immunochemistry to examine the distribution of
pyridoxal kinase in rabbit brain with the following results: “The cytoplasm of
neuronal cells and neuroglial cells in the cerebral cortex, hippocampal region, brain
nuclei and cerebellar cortex showed positive staining with various degrees of
intensity. The neuronal cells and surrounding ﬁbers in some brain nuclei, such as
the area tegmentalis ventralis or the substantia nigra, showed intense staining. The
neuronal cells of the hippocampal region showed somewhat weak reactivity, but
some with intense reactivity were found sparsely distributed and positive staining
ﬁber networks of a very low density were also observed.” Pyridoxal kinase activity
in brain changes with dietary intake. Spector and Shikuma (1978) suggested that a
report of a negative correlation between pyridoxal phosphate and pyridoxal kinase
in rabbit brain (Ebadi et al. 1970) was due to errors caused by using pyridoxal rather
than pyridoxine as the substrate for analyzing kinase activity. When various areas of
normal rat brain were compared, there was a positive correlation between pyridoxal
kinase activity and pyridoxal phosphate concentration (Ebadi and Bifano 1978). An
early report suggested that dietary deﬁciency of vitamin B-6 in rats tended to
increase kinase activity in brain slightly (McCormick et al. 1961). Later work by
Meisler and Thanassi (1980) indicated that vitamin B-6 deﬁciency reduced both
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pyridoxal phosphate and pyridoxal kinase activity in rat brain. Pyridoxal 5′-phos-
phate synthase and phosphatase activities did not show any consistent changes. The
animals weighed about 100 g at the start of the experiment. By the 4th week brain
kinase activity in both the control and deﬁcient groups increased and the group
differences were no longer statistically signiﬁcant. Restoring normal vitamin B-6
intake quickly restored kinase activity to control values in the liver. As noted above
kinase activity in brain had already increased and supplementation had little
additional effect. Rasmussen et al. (1979) also found that pyridoxal synthase
activity was not affected by vitamin B-6 deﬁciency. Without citing any speciﬁc
references Meisler and Thanassi (1980) state that studies reported by others have
shown that pyridoxal 5′-phosphate synthase is involved in regulating pyridoxal
phosphate in B-6 sufﬁcient animals and that their current results indicated pyridoxal
kinase is a regulatory factor in vitamin B-6 deﬁciency. Those suggestions have
recently been cited by Kwak et al. (2009). It is important to note that product
inhibition of pyridoxal 5′-phosphate synthase will occur only when the substrate is
pyridoxine phosphate or pyridoxamine phosphate. Pyridoxal 5′-phosphate synthase
is not required for the production of pyridoxal phosphate from pyridoxal. In
unsupplemented humans there is little or no pyridoxine or pyridoxamine in the
peripheral plasma or cerebrospinal fluid (Albersen et al. 2014). Therefore, most of
the pyridoxal phosphate in brain arises from pyridoxal which would limit the role of
pyridoxal 5′-phosphate synthase as a regulator. In addition we would suggest that
since pyridoxal kinase activity responds rapidly to changes in vitamin B-6 intake,
vitamin B-6 availability rather than pyridoxal kinase is the regulator.
The vitamin B-6 analog, 4′-deoxypyridoxine, can act as either a competitive
inhibitor or a competing substrate depending on the reaction in question.
Unfortunately, the distinction is frequently ignored in the literature. Ebadi et al.
(1970) noted that pyridoxal kinase activity was increased in the presence of de-
oxypyridoxine and that the increase was prevented by actinomycin D or puromycin.
While Ebadi et al. (1970) interpreted the results as an inverse relationship between
pyridoxal phosphate and kinase activity, we suspect that since deoxypyridoxine is a
substrate for the kinase, the presence of deoxypyridoxine may have stimulated the
increased synthesis of pyridoxal kinase. Pyridoxal kinase from rat brain is also
inhibited by dopa, dopamine, norepinephrine, tyramine, serotonin, histamine, and
GABA (Ebadi and Govitrapong 1979). Kerry et al. (1986) attributed an increase in
kinase activity during isolation from sheep brain to removal of interfering sub-
stances such as amines. Based on the above discussion we suggest that vitamin B-6
intake, protein binding, phosphatase activity and biogenic amines may be the prime
regulators of intracellular pyridoxal phosphate concentration in brain. Post mortem
examination of over 100 human brains detected a 1000-fold range of pyridoxal
kinase activity (Snell 1964). Snell noted that pyridoxal kinase is quite stable in
frozen samples but does not provide any documentation that all of the brains were
subject to the same post mortem protocol prior to freezing the samples.
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11.6 Vitamin B-6 and Seizures
The earliest symptoms of vitamin B-6 deﬁciency are skin disorders, seizures and
anemia. Brain does not conserve vitamin B-6 as well as muscle during severe
dietary vitamin B-6 deﬁciency. Early studies of vitamin B-6 deﬁciency reported
seizures in dogs (Fouts et al. 1938), pigs (Chick et al. 1938) and rats (Chick et al.
1940). In humans seizures have been observed as a result of dietary vitamin B-6
deﬁciency (Coursin 1955) and genetic disorders of vitamin B-6 metabolism (Footitt
et al. 2013; Dakshinamurti and Dakshinamurti 2014). Electroencephalographic
changes were noted within 2 weeks in women fed a diet containing essentially no
vitamin B-6 (Kretsch et al. 1991). The changes were corrected with an intake of
0.5 mg vitamin B-6/d. Gregory et al. (2013) recently fed human subjects 0.37 mg
vitamin B-6/d for 28 days. with no reported clinical effects. They did not report
electroencephalographic data. In a milder restriction in which rats were fed 60 % as
much as controls for up to 40 weeks there were no signiﬁcant differences in the
pyridoxal phosphate or pyridoxamine phosphate content of brain (Wei 1999).
Sakurai et al. (1980b) examined the interactions between vitamin B-6 and
penicillamine, thiosemicarbazide and semicarbazide in mouse brain. Doses of
2000 µmol penicillamine/kg, 165 µmol thiosemicarbazide or 1790 µmol
semicarbazide/kg were lethal. Simultaneous subcutaneous administration of
250 µmol pyridoxine, pyridoxal or pyridoxamine/kg prevented both seizures and
death from penicillamine or thiosemicarbazide but did not protect against semi-
carbazide. All three drugs reduced brain pyridoxal phosphate 20–50 % from the
control value of about 10 nmol/g. This decrease following penicillamine or thio-
semicarbazide was prevented by administration of 250 µmol pyridoxine, pyridoxal
or pyridoxamine/kg. The authors do not speculate about why the B-6 vitamers did
not prevent the effects of semicarbazide. Intramuscular administration of pyridoxine
or pyridoxamine alone did not increase pyridoxal phosphate above the baseline
value of about 10 nmol/g. Administration of pyridoxal caused a slight decrease in
pyridoxal phosphate during the peak pyridoxal concentration, possibly indicating
substrate inhibition. Pyridoxamine phosphate remained about 14 nmol/g in all
treatments suggesting that pyridoxamine phosphate is not in rapid equilibrium with
pyridoxal phosphate and cannot compensate for a rapid decrease in pyridoxal
phosphate. Peak brain content of pyridoxal was about 27, 8 and 2 nmol/g following
intramuscular administration of 250 µmol/kg of pyridoxal, pyridoxine and pyri-
doxamine, respectively. Peak content of pyridoxamine was less than 2 nmol/g with
each vitamer. Pyridoxamine was the only vitamer which increased pyridoxamine
phosphate. Even though pyridoxamine alone produced very little change from the
baseline vitamin B-6 content of the brain, it was just as effective as pyridoxine and
pyridoxal in preventing the decrease in pyridoxal phosphate produced by penicil-
lamine and thiosemicarbazide. It seems likely although there was not a large
increase in pyridoxal, there was enough to correct the deﬁcit produced by the drugs.
Mizuno et al. (1980) found that the vitamin B-6 analogs which were the most
effective competitive substrates for pyridoxal kinase also were most effective in
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producing seizures in mice thus demonstrating the importance of pyridoxal phos-
phate in preventing seizures.
As noted earlier a role for TNAP was suggested by the occurrence of seizures in
neonatal hypophosphatasia. This was conﬁrmed in knockout mice lacking TNAP
which died from seizures (Waymire et al. 1995). Pyridoxal phosphate in cerebro-
spinal fluid was above the normal range in three infants with hypophosphatasia
(Baumgartner-Sigl et al. 2007; Hofmann et al. 2013; Belachew et al. 2013) sup-
porting the hypothesis that low alkaline phosphatase activity restricted uptake of
vitamin B-6 by the brain. Waymire et al. (1995) hypothesized that the seizures
resulted from decreased concentration of the inhibitory neurotransmitter,
gamma-aminobutyrate (GABA). GABA is produced from glutamic acid by gluta-
mate decarboxylase (EC 4.1.1.15), which requires pyridoxal phosphate. After being
released into the synaptic cleft GABA is taken up by adjoining astrocytes where it is
converted to succinate semialdehyde and glutamate by 4-aminobutyrate-2-oxo-
glutarate transaminase (EC 2.6.1.19) (Baxter 2003), which also requires pyridoxal
phosphate. The glutamate is then converted to glutamine by glutamate-ammonia
ligase (EC 6.3.1.2) which is located primarily in the astrocytes (Suarez et al. 2002).
The glutamine may return to the neurons for reuse.
Two forms of glutamic acid decarboxylase (EC 4.1.1.15) with complex regu-
lation occur in GABA-ergic neurons (Martin and Rimvall 1993). GAD67 is cyto-
solic and distributed throughout the cell body. GAD65 is concentrated in the nerve
terminal and is reversibly anchored to the membrane of synaptic vesicles. GAD65
in brain accounts for the large fraction of the enzyme which occurs in brain as the
apoenzyme thus serving as a reserve supply. GAD67 is more highly saturated with
cofactor. ATP stimulates the formation of apoenzyme while inorganic phosphate
facilitates formation of the holoenzyme. Elimination of GAD67 results in lethal
developmental defects including cleft palate and respiratory failure (Kash et al.
1997). Mice lacking GAD65 appear normal at birth with normal GABA and
holo-GAD activity. However, the increase in activity associated with added pyri-
doxal phosphate is reduced indicating a decrease in total enzyme protein. The mice
have increased susceptibility to seizures. Genetic studies in mice led Kash et al.
(1997) to conclude that the relative contribution of GABA synthesized by GAD65
is genetically determined and that the resulting seizure activity involves the limbic
region. GABA may also have a role in the synaptic integration of newly generated
neurons in adult brain (Ge et al. 2006). Sharma and Dakshinamurti (1992) presented
a thorough discussion of the electroencephalographic changes associated with
vitamin B-6 deﬁciency. Seizures induced by picrotoxin, pentylenetetrazol or do-
moic acid in control or vitamin B-6 deﬁcient rats could be prevented by local
administration of pyridoxine or GABA in the thalamic VPL region or the hippo-
campal CA3 region indicating that GABA deﬁciency was a signiﬁcant factor in
seizure development.
At 10–14 days postnatal brain GABA concentrations were reduced 50 % in
TNAP knockout mice compared to normal controls (Waymire et al. 1995).
Similarly, in an infant with hypophosphatasia and West syndrome GABA was less
than 0.005 nmol/mL in the cerebrospinal fluid (Yamamoto et al. 2004). GABA
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concentrations were also low in the cerebrospinal fluid of infants with pyridoxine
dependent seizures (Kurlemann et al. 1992) and West syndrome (Kurlemann et al.
1997) prior to treatment with pyridoxine. Initial attempts to rescue the mice with
pyridoxine had limited success presumably because the primary metabolic pathway
involved phosphorylation followed by oxidation to pyridoxal phosphate. With oral
administration this occurs primarily in the liver which releases pyridoxal phosphate
into the plasma. Hydrolysis of the resulting plasma pyridoxal phosphate would be
limited by the lack of alkaline phosphatase thus reducing the availability of pyri-
doxal for transfer into the brain. Plasma pyridoxal was reduced 10-fold in the
knockout mice. Use of pyridoxal in place of pyridoxine was much more effective
since it could be transported directly into the brain. In liver, kidney, heart and
muscle of the knockout mice pyridoxal phosphate was 50–60 % of control values.
In brain it was only 35 % of control indicating that brain was affected more than
other tissues. Pyridoxal phosphate concentrations in the brains of two infants with
hypophosphatasia were slightly lower than in a single normal infant (Whyte et al.
1988). Litmanovitz et al. (2002) suggested that the normal concentrations in the
infants might reflect higher residual alkaline phosphatase activity. The ratio of
pyridoxal phosphate in plasma/cerebrospinal fluid was about 2.5 in normal subjects
ranging in age from 0 to 68 years (Shin et al. 1984). Patients with vitamin B-6
related seizures tended to have lower cerebrospinal fluid values and higher plasma
values yielding a plasma/cerebrospinal fluid ratio of 21. It is interesting to note that
an infant with hypophosphatasia and pyridoxine responsive seizures had a ratio of
36 (Baumgartner-Sigl et al. 2007) even though the concentration of pyridoxal
phosphate in the spinal fluid was 57 nmol/L compared with their cited normal range
of 7–39 nmol/L (Shin et al. 1984). This suggests that the ratio may be a more
reliable marker of potential seizures than the cerebrospinal fluid value alone.
Baumgartner-Sigl et al. (2007) noted that all reported cases of hypophosphatasia
with neonatal seizures died by 18 months of age. Di Mauro et al. (2002) found that
various TNAP mutations differed in their ability to hydrolyze pyridoxal phosphate.
This could help to explain the variable occurrence of seizures in hypophosphatasia.
While vitamin B-6 deﬁciency can cause seizures, excesses are also neurotoxic.
Pyridoxal phosphate causes seizures in immature mice by blocking GABA recep-
tors (Ishioka et al. 1995). The authors suggested the immature blood brain barrier
allowed passage of pyridoxal phosphate. Such leakage does not appear to occur in
hypophosphatasia. High doses of pyridoxine cause neuropathy in rats (Callizot
et al. 2001), dogs (Chung et al. 2008) and humans (Gdynia et al. 2008). There is
one case report of pyridoxine responsive seizures in an infant whose mother con-
sumed 80 mg pyridoxine/d during her pregnancy (South 1999b). However, the
causal relationship was questioned (Baxter and Aicardi 1999; South 1999a). It is
interesting that while pyridoxamine has been proposed as a treatment for the side
effects of diabetes produced by advanced glycation end products (Chen and Francis
2012), pyridoxine intoxication has been recommended as a model for diabetic
sensory neuropathy (Callizot et al. 2001).
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11.7 Other Aspects of Vitamin B-6 Metabolism in Brain
While reduced synthesis of GABA resulting from decreased intracellular availability
of pyridoxal phosphate appears to be a major factor in the seizures observed in
neonatal hypophosphatasia, it is appropriate to be aware of several additional aspects
of vitamin B-6 metabolism in brain. Two good summaries of earlier work are
available (Ebadi and Costa 1972; Ebadi 1981). Ebadi (1981) noted that vitamin B-6
is involved in the synthesis or metabolism of multiple neurotransmitters in addition
to GABA including dopamine, norepinephrine, serotonin, tyramine, tryptamine,
taurine, histamine and even acetyl choline indirectly. He also noted that vitamin B-6
is involved in the synthesis of growth hormone, follicle-stimulating hormone,
luteinizing hormone in the brain as well as aldosterone, glucagon, cortisol, estradiol,
testosterone and epinephrine in other tissues. The following discussion will focus on
information that is more recent or particularly relevant to the focus of this book.
11.7.1 Additional Regulatory Mechanisms
In the commentary following the 1981 review (Ebadi 1981) Metzler (1981) dis-
cusses the complexities of vitamin B-6 chemistry and potential interactions.
Pyridoxamine phosphate is usually bound to enzymes less tightly than pyridoxal
phosphate. Glutamate decarboxylase in brain is rapidly deactivated in the presence
of glutamate (Miller et al. 1978; Seligmann et al. 1978). Metzler suggests that this
could be the result of a side reaction involving decarboxylative transamination which
would convert pyridoxal phosphate to pyridoxamine phosphate followed by disso-
ciation of the cofactor from the enzyme. Reactivation of the enzyme would depend
on the availability of pyridoxal phosphate which in turn would depend at least in part
on oxidation of pyridoxamine phosphate back to pyridoxal phosphate. Metzler also
notes that the apoenzymes are often degraded more rapidly than the holoenzyme.
Therefore, the interactions between pyridoxal phosphate and pyridoxamine phos-
phate could have some complex regulatory functions. ATP and ADP at concentra-
tions comparable to intracellular values inhibit the association of pyridoxal
phosphate with glutamate dehydrogenase raising the possibility that decarboxylase
activity might be influenced by energy metabolism (Seligmann et al. 1978). Glucose
deprivation of cultured hippocampal cells causes reduced ATP, increased extracel-
lular glutamate with NMDA receptor activation and release of lactic dehydrogenase
indicating cell death (Geng et al. 1997). Pyridoxal phosphate prevented these
changes by increasing pyruvate presumably through increased alanine aminotrans-
ferase activity. Pyridoxal phosphate also inhibits the citrate transporter thus keeping
citrate in the mitochondria where it can be used to generate ATP. Maintaining
adequate ATP prevented the other consequences of glucose deprivation. Based on
these observations Geng et al. (1997) suggested that pyridoxal phosphate treatment
might help to minimize neuronal death in some metabolic disorders.
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11.7.2 Developmental Effects
There is a variety of evidence suggesting that limiting the vitamin B-6 supply in the
brain can have effects in addition to reduced production of GABA. In studies in
knockout mice lacking alkaline phosphatase Narisawa et al. (2001) found that
pyridoxal treatment improved the appearance of lumbar nerve roots. Creation of a
dietary vitamin B-6 deﬁciency in normal mice also caused seizures and thinning of
nerve roots. Vitamin B-6 deﬁciency reduces synthesis of sphingolipids and inter-
feres with formation of myelin (Stephens and Dakshinamurti 1975) raising the
possibility that limited vitamin B-6 in neonatal hypophosphatasia could have
developmental effects in addition to causing seizures. Narisawa et al. (2001) cited
unpublished results showing that TNAP is produced in the neonatal mouse intestine
until it is replaced by the intestinal isoenzyme around post-natal day 14–15 sug-
gesting that TNAP knockout mice might have reduced absorption of pyridoxal
phosphate from milk. We could not locate any data on the pyridoxal phosphate
content of mouse milk. There is an inverse relationship between alkaline phos-
phatase activity and the pyridoxal phosphate content of milk in rats, goats, pigs, and
cows (Coburn et al. 1992) indicating that these species release signiﬁcant amounts
of pyridoxal phosphate into the milk. However, human milk was low in both
alkaline phosphatase activity and pyridoxal phosphate suggesting that very little
pyridoxal phosphate is released into the milk.
Analysis of cerebrospinal fluid in infants with hypophosphatasia detected
reduced 5-hydroxyindoleacetic acid and homovanillic acid in two out of four cases
(Balasubramaniam et al. 2010; Hofmann et al. 2013; Belachew et al. 2013).
3-O-methyldopa and 5-hydroxytryptophan were elevated in the only cases where
they were measured (Baumgartner-Sigl et al. 2007; Balasubramaniam et al. 2010).
These data suggest that multiple vitamin B-6 pathways in the brain are probably
altered in hypophosphatasia.
There has been some interesting work on the role of vitamin B-6 during
development in rats. When female rats were fed a diet containing 0.7 mg pyridoxine
hydrochloride/kg during gestation and lactation, the pups exhibited seizures from
day 12 to day 18 after which the seizures stop (Guilarte 1989). The same diet failed
to produce seizures in adult rats. At day 14 the total vitamin B-6 content of most
brain areas in low intake animals was about 40 % of controls. However, by day 56
most areas had increased to 60 % of controls with substantia nigra and cerebellum
exceeding 80 % of control values even though the rats remained on the low intake
diet. GABA was signiﬁcantly below control values in all brain regions at both 14
and 28 days even though there were no seizures at 28 days. By 56 days only the
pons/medulla region was signiﬁcantly below control GABA levels. These data
suggest that decreased GABA concentrations may be a necessary but not sufﬁcient
factor in causing seizures. Glutamate was signiﬁcantly reduced in the cortex, hip-
pocampus, substantia nigra and pons/medulla at 14 days but not at 28 days. Glycine
was signiﬁcantly elevated in the hippocampus and caudate/putamen areas at
14 days but not at 28 days. Taurine was signiﬁcantly reduced in the cortex,
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caudate/putamen, and substantia nigra at 14 days but not at 28 days. Interactions
between these and other metabolites may interact with GABA to generate seizures.
When dams and pups were fed a diet containing 0.6 mg pyridoxine
hydrochloride/kg, pyridoxal phosphate content of various brain regions at 7 days
postnatal was 66–90 % of control values (Groziak et al. 1984). By day 15 the values
declined to 15–33 % of controls after which they gradually increased. In control
animals pyridoxal phosphate concentration approximately doubled during day 7–
15. Brain weight increased by about 80 % in both groups. Therefore, total brain
pyridoxal phosphate in the controls increased almost 4 times from day 7 to day 15.
However, total pyridoxal phosphate in the 0.6 group remained essentially constant.
This suggests that inability to supply adequate vitamin B-6 to new tissue resulted in
a decline in vitamin B-6 content which may have contributed to the
seizures Guilarte (1989) observed from 12 to 18 days. Pyridoxal kinase activity in
rat brain increases about three times from birth to day 15 (Ebadi 1972). This
increase may have allowed the tissues to accumulate sufﬁcient vitamin B-6 to
eliminate the seizures after 18 days even with limited vitamin B-6 intake. Four
additional reports (Loo 1972; Bayoumi and Smith 1976; Bhagavan et al. 1977;
Guilarte 1989) also found increasing pyridoxal phosphate in postnatal rat brain
making it difﬁcult to reconcile the data from Ebadi (1972) showing a marked
decrease over the same period.
Pyridoxal kinase activity in human brain increases about 20-fold from 6 to
11 weeks of gestation (Bukin and Ivanova 1976). Activity in the medulla oblongata
was about twice whole brain activity by 8 weeks and that difference was maintained
into the second trimester. Activity in the medulla changed little from the second to
third trimester while other brain areas increased to match or surpass it. By the
second trimester activity in the hippocampus was also signiﬁcantly higher than in
the frontal lobe. By the third trimester activity in most brain areas had increased to
eliminate these differences. However, activity in the cerebellar cortex was signiﬁ-
cantly below the frontal lobe. In bovine brain the cerebellar medulla rather than the
cortex had low kinase activity (Table 11.3).
Although some reports (Bayoumi et al. 1972; Ruth and Morgan 1986) did not
observe seizures in vitamin B-6 deﬁcient adult rats, Sharma and Dakshinamurti
Table 11.3 Pyridoxal kinase
content of bovine brain
(McCormick et al. 1961)
Tissue Activity (nmol/h·g)
Cerebrum
Hemisphere 1620
Diencephalon 1184
Mesencephalon 1008
Cerebellum
Cortex 1368
Medulla 235
Brain stem
Pons 436
Medulla oblongata 364
224 S.P. Coburn
(1992) detected electroencephalographic changes indicating that seizures would
likely have developed if the deﬁciencies were extended. Based on these observa-
tions the current author suggests that the decreased susceptibility to seizures in adult
rats is influenced by the slower rate of growth and the severity of the deﬁciency.
11.7.3 Pyridoxamine Phosphate
As noted earlier pyridoxamine phosphate is a signiﬁcant component of most tissues
other than muscle. Perhaps the most extreme example is in the neocortex of 30 days
old rat pups in which pyridoxamine phosphate was 4–5 times higher than pyridoxal
phosphate (Groziak and Kirksey 1987). In mouse brain most of the pyridoxamine
phosphate was in the mitochondria while pyridoxal phosphate was found primarily
in the cytosol as was most of the pyridoxal kinase activity (Rott et al. 1960).
Pyridoxal phosphatase activity was mainly in the mitochondria. Lyon et al. (1962)
found that 75 % of the pyridoxamine phosphate in mouse brain was associated with
the mitochondria. When I-strain mice, which are susceptible to audiogenic seizures,
received a vitamin B-6 deﬁcient diet, pyridoxal phosphate in the brain declined but
pyridoxamine phosphate remained constant. Lyon et al. concluded that pyridox-
amine phosphate was not serving as a storage form since it was not released during
vitamin B-6 deﬁciency. Similarly, after growing, pair-fed rats received a diet
completely lacking vitamin B-6 for 2 weeks total brain B-6 declined about 26 %
(Sampson and O’Connor 1989). However, pyridoxal phosphate declined about
46 % while pyridoxamine phosphate declined only 13 %. In the brains of TNAP
deﬁcient knockout mice pyridoxal phosphate was decreased to 35 % of control
values while pyridoxamine phosphate was 65 % of controls (Waymire et al. 1995).
While pyridoxamine phosphate may be more resistant to depletion, when rats were
exposed to a low vitamin B-6 diet throughout gestation and lactation, all B-6
vitamers were signiﬁcantly reduced in the neocortex at 30 days postnatal (Groziak
and Kirksey 1987). Since tracer studies in mice indicated very limited production of
pyridoxamine, Colombini and McCoy (1970) concluded that pyridoxamine phos-
phate was produced primarily from pyridoxal phosphate.
In Guinea pig cortex the major B-6 vitamers were pyridoxamine phosphate
(7.5 nmol/g), pyridoxal phosphate (4.75 nmol/g) and pyridoxal (1.4 nmol/g) (Loo
and Mack 1971). The subcellular distribution for pyridoxamine phosphate was
nucleus (18.1 %), crude mitochondria (63.4 %) and supernatant (18.5 %) while
pyridoxal phosphate was nucleus (12.4 %), mitochondria 39.1 % and supernatant
48.5 %. Fractionation of the crude mitochondria indicated that both pyridoxamine
phosphate and pyridoxal phosphate were divided about equally between the syn-
aptosomes and the extra terminal mitochondria. In the synaptosomal organelles
pyridoxamine phosphate (2.83 nmol/g) was detected primarily in the cytoplasm
(19.6 %), presynaptic membranes (29.3 %) and the mitochondria (47.3 %) while
pyridoxal phosphate (2.40 nmol/g) was distributed in the cytoplasm (41.6 %),
presynaptic membranes (12.0 %) and mitochondria (41.6 %). Rat tissue gave
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similar results. Loo et al. (1971) suggested that the occurrence of pyridoxamine
phosphate and pyridoxal phosphate in the membranes might indicate a carrier
function for amino and keto acids. Sakurai et al. (1980a) provided a detailed
examination of the subcellular distribution of vitamin B-6 in mouse brain
(Table 11.4). Using microbiological analysis pyridoxal phosphate was the dominant
vitamer in whole brain. In the crude mitochondrial fraction pyridoxamine phosphate
was highest in the extraterminal mitochondria while in the synaptosomal fraction it
was higher in the synaptoplasma than in the intraterminal mitochondria. Although
pyridoxine phosphate concentrations were no more than 5 % of pyridoxal phos-
phate or pyridoxamine phosphate, the fact that pyridoxine phosphate concentrations
were highest in the myelin and synaptic vesicle fractions led Sakurai et al. to
suggest that pyridoxine phosphate may have a role in nervous system conduction.
11.7.4 Phosphoethanolamine Metabolism
One of the consequences of hypophosphatasia is increased phosphoethanolamine in
serum and/or urine. Phosphoethanolamine excretion can be influenced by vitamin
B-6 as well as alkaline phosphatase. Ethanolamine-phosphate phospho-lyase (EC
4.2.3.2) utilizes pyridoxal phosphate to convert phosphoethanolamine to acetalde-
hyde, ammonia and inorganic phosphate (Fleshood and Pitot 1970). Enzyme iso-
lated from rabbit liver had an optimal pH of 7.8, Km of 0.61 mM for
Table 11.4 Subcellular distribution of vitamin B-6 in mouse brain (Sakurai et al. 1980a)
Fraction Protein
(mg/g brain)
Vitamer (pmol/mg protein)
PL PLP PM PMP PN PNP
Whole brain 122 5.26 80.7 0.638 60.6 0.091 0.436
Nucleus 43.2 3.87 60.9 0.484 41.2 0.079 0.371
Crude
mitochondria
49.4 5.67 104.7 0.619 62.9 0.096 0.413
Microsomes 7.5 6.73 30.7 2.39 27.0 0.194 0.634
Cytosol 22.6 23.68 128.3 3.17 42.2 0.251 0.866
Fractionation of crude mitochondria
Myelin 3.77 2.96 37.2 5.77 48.3 0.199 1.93
Synaptosomes 24.12 4.82 51.4 1.53 51.5 0.097 0.325
Extraterminal
mitochondria
11.36 6.06 129.6 3.82 129.8 0.173 0.774
Fractionation of synaptosomes
Synaptoplasma 2.89 48.2 172 4.61 147 0.966 1.13
Synaptic vesicles 1.21 9.77 53 14.7 67.7 1.43 1.97
Intraterminal
mitochondria
5.35 3.65 105 2.72 75.6 0.241 0.382
Abbreviations for vitamers are listed in Table 11.1
226 S.P. Coburn
phosphoethanolamine, Km of 0.27 μΜ for pyridoxal phosphate and Ki of 1.3 mM
for inorganic phosphate. Rats fed a high protein, vitamin B-6 deﬁcient diet devel-
oped osteoporotic changes and markedly increased excretion of phosphoethanol-
amine with no changes in serum alkaline phosphatase activity (Benke et al. 1972).
Recently, AGXT2L1, a pyridoxal phosphate brain protein related to alanine gly-
oxylate aminotransferase, has been shown to be an ethanolamine-phosphate
phospho-lyase (Veiga-da-Cunha et al. 2012; Schiroli et al. 2013). AGXT2L1 was
the most consistently upregulated gene in the brains of deceased patients with
schizophrenia or bipolar disorder (Shao and Vawter 2008) and was the most
upregulated gene in mouse brain after treatment with lithium (McQuillin et al. 2007).
This is an example of an enzyme from a generalist family [class II aminotransferases
(Mehta and Christen 2000)] which has become highly speciﬁc. Nam et al. (2012)
noted that specialist enzymes are frequently essential, maintain higher metabolic
flux, and require more regulation to control metabolic flux in dynamic environments.
Schiroli et al. (2013) suggested that the need for strict regulation in the case of
AGXT2L1 might result from the fact that the reaction is irreversible and generates
potentially toxic products. They noted that phosphoethanolamine is a product of
sphingolipid degradation and a substrate for glycerophospholipid biosynthesis.
Ethanolamine and phosphoethanolamine can interfere with mitochondrial function
(Modica-Napolitano and Renshaw 2004). The fact that AGXT2L1 requires pyidoxal
phosphate raises the possibility that the increased phosphoethanolamine observed in
hypophosphatasia could be exacerbated by low vitamin B-6 in addition to the lack of
alkaline phosphatase particularly in infants where seizures suggest the existence of
vitamin B-6 deﬁciency. We are unaware of any data on AGXT2L1 activity in
hypophosphatasia. Although alterations in phosphoethanolamine metabolism have
been associated with neuropsychiatric disorders (Miller et al. 2012) and most of the
previous references to AGXT2L1 deal with such disorders, there is little evidence
that neuropsychiatric problems are increased in hypophosphatasia. Since signs of
vitamin B-6 deﬁciency in hypophosphatasia seem to be limited to infants, the
duration of any reductions in AGXT2L1 might be too short to cause neuropsychi-
atric problems in surviving infants. The Uniprot data base (http://www.uniprot.
org/uniprot/?query=ethanolamine-phosphate+phospho-lyase&sort=score) contains
5 reviewed entries for AGXT2L1 from human, mouse, bovine, zebraﬁsh and African
clawed frog all indicating the subcellular location as mitochondrion. Sia et al. (1975)
reported that pyridoxine supplementation reduced phosphoethanolamine excretion
in the parents of an infant with neonatal hypophosphatasia by 25–69 %.
Administration of pyridoxine to the infant reduced the seizures but did not reduce
phosphoethanolamine excretion. Prior to pyridoxine therapy neither the infant nor
the parents had detectable degradation of phosphoethanolamine in serum. In vitro
degradation of phosphoethanolamine was maximally stimulated by addition of 10−5
M pyridoxal phosphate. Control serum required 10−3 M to obtain a comparable
effect. Addition of pyridoxal phosphate had no effect on the degradation of
p-nitrophenol-phosphate. Based on these results Sia et al. (1975) recommended
further study of the beneﬁts of pyridoxine supplementation in hypophosphatasia.
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11.7.5 Inflammation
It has been suggested that inflammation increases the demand for vitamin B-6 from
plasma for increased metabolism of tryptophan to anthranilic acid and
3-hydroxyanthranilic acid (Paul et al. 2013; Reginaldo et al. 2013). A study of
inflammation in hypophosphatasia showed that calcium pyrophosphate but not
pyridoxal phosphate increased prostaglandin E2 synthesis in cultured skin and dura
mater cells (Girschick et al. 2006). The authors concluded that high pyridoxal
phosphate in hypophosphatasia did not cause inflammation. However, their data
show that prostaglandin production by hypophosphatasia tissues in the presence of
calcium pyrophosphate tended to be slightly lower when pyridoxal phosphate was
administered with calcium pyrophosphate. This raises the possibility that the pyr-
idoxal phosphate may have reduced rather than enhanced the response. Since the
hypophosphatasia tissues presumably have limited ability to hydrolyze pyridoxal
phosphate, it would be interesting to repeat the studies using pyridoxal in place of
pyridoxal phosphate to determine whether increased availability of pyridoxal would
reduce the inflammatory response.
11.7.6 Long Term Potentiation
Vitamin B-6 appears to be associated with long-term potentiation which in turn is
associated with learning and memory. Immunoreactivity of pyridoxal 5′-phosphate
synthase but not pyridoxal kinase was increased in the dentate gyrus of rats after
induction of long-term potentiation (Kwak et al. 2009). Injection of pyridoxine,
pyridoxal or pyridoxamine had no effect on development of long term potentiation
in rat brain. Injecting pyridoxal phosphate produced multiple population spikes
which were attributed to disruption of GABAA receptor mediated inhibition.
Transduction of Tat-pyridoxal kinase did not affect induction of long-term poten-
tiation. However, transduction of Tat-pyridoxal 5′-phosphate synthase increased the
efﬁciency of long-term potentiation induction. The authors concluded that because
Tat-pyridoxal 5′-phosphate synthase injection did not affect fast or late paired-pulse
inhibitions, the upregulation of pyridoxal 5′-phosphate synthase may not be related
to GABAergic inhibition. They did not report any measurements of pyridoxal
phosphate concentrations. Serine racemase (EC 5.1.1.18) provides D-serine for the
N-methyl-D-aspartate receptor which mediates neurotransmission, synaptic plas-
ticity, cell migration and long term potentiation. Altered D-serine concentrations are
associated with neuropathologies, aging deﬁcits, and disorders including schizo-
phrenia, amyotrophic lateral sclerosis, Alzheimer’s disease and stroke (Campanini
et al. 2013). The involvement of pyridoxal phosphatase/chronophin was mentioned
earlier. It is interesting that alkaline phosphatase activity has also been associated
with activity dependent functions in the cortex (Fonta et al. 2004).
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11.7.7 Homocysteine
Vitamin B-6 is also related to homocysteine metabolism. A genome-wide assess-
ment of the relationship between vitamin B-6, folate, vitamin B-12 and homo-
cysteine detected a signiﬁcant relationship between the C allele of the ALPL gene
and reduced vitamin B-6 (Tanaka et al. 2009). Recent results showed that sup-
plementation with folate, vitamin B-6 and vitamin B-12 reduced cerebral atrophy in
gray matter in elderly subjects with increased dementia risk and elevated homo-
cysteine (Douaud et al. 2013).
11.7.8 Lysosomal Enzymes
Vitamin B-6 deﬁciency increased lysosomal enzymes in rat brain (DiPaolo et al.
1975). Faber et al. (1991) suggested that vitamin B-6 might be involved in the
synthesis of mannose phosphate marker or receptor proteins on lysosomes which
dictate the disposition of lysosomal enzymes.
11.8 Pyridoxal Phosphate and Purinoceptors
The interaction between alkaline phosphatase and purinoceptors is discussed else-
where in this book (See Chaps. 4 and 13). Pyridoxalphosphate-6-azophenyl-2′,4′-
disulphonic acid is widely used as a purinoceptor antagonist raising the possibility
that there might be some physiological interactions between purinoceptors and
pyridoxal phosphate. In discussing metabolic errors in vitamin B-6 metabolism
Surtees (2006) asked whether pyridoxal phosphate might have a noncofactor role,
possibly interacting with ion channels or pumps. Trezise et al. (1994) concluded that
pyridoxal phosphate acts as a speciﬁc inhibitor of P2 purinoceptors in the vagus
nerve and vas deferens of rats. Pyridoxal phosphate had an effect at concentrations
equal to those of α, β-methylATP.Wang et al. (1999) found that pyridoxal phosphate
was an ATP receptor antagonist in rat cardiomyocytes. Binding of 10 μΜ ATP-S to
low afﬁnity binding sites was signiﬁcantly reduced by 1 μΜ pyridoxal phosphate.
Wang et al. (1999) concluded that since normal plasma concentrations of pyridoxal
phosphate range from 24 to 81 nM, pyridoxal phosphate probably would not
function as an inhibitor under physiological conditions. However, they also noted
that the higher ATP concentrations that were needed in the intact heart and
cardiomyocytes than in the sarcolemmal membranes might result from ATP
hydrolysis thus suggesting that the effective concentration of ATP might be lower
than the administered amount. P2X2 and P2X2/3 receptors expressed in HEK293
cells were inhibited by pyridoxal phosphate with an IC50 of 7 and 13 µM, respec-
tively (Theriault et al. 2014). In a phase 2 clinical trial pyridoxal phosphate (250 mg
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or 750 mg/d) was administered orally beginning 3 to 10 h prior to coronary bypass
graft surgery and continuing for 30 days (Tardif et al. 2007). The 250 mg treatment
did not signiﬁcantly affect the prespeciﬁed primary end point but was associated
with a signiﬁcant reduction in perioperative myocardial infarction with creatine
kinase-myocardial band ≥100 ng/mL. The 250 mg dose was more effective than
750 mg. An editorial discussing those results suggested that improved efﬁcacy may
require targeting multiple receptors or perhaps a central control point in the relevant
metabolic pathway (Verrier 2007). Pyridoxal phosphate may also interact with
calcium channels (Dakshinamurti et al. 1998). Microinjection of pyridoxal phos-
phate causes seizures which were attributed to extracellular pyridoxal phosphate
interacting with GABAA receptor (Salazar and Tapia 2001).
11.9 Hyperphosphatasia
Considering the marked elevation of plasma pyridoxal phosphate in hypophos-
phatasia, one might expect markedly reduced concentrations in hyperphosphatasia
resulting from a defect in the biosynthesis of the phosphatidylinositol glycan anchor
which attaches the enzyme to the membrane (Thompson et al. 2012) (see also
Chap. 16). However, that does not appear to be the case. Thompson et al. (2010)
reported only one out ﬁve patients with low pyridoxal phosphate and pyridoxine
responsive seizures. That patient had the lowest relative phosphatase activity of any
of the patients. Hydrolysis of pyridoxal phosphate was increased in plasma of
subjects with increased alkaline phosphatase activity due to liver or bone disorders
(Anderson et al. 1980). There was a negative correlation between endogenous
plasma pyridoxal phosphate and alkaline phosphatase activity (r = −0.893).
Increased hydrolysis of plasma pyridoxal phosphate is not necessarily a problem
unless it increases the net loss of vitamin B-6 from the body. Additional data will be
needed to clarify vitamin B-6 metabolism in hyperphosphatasia.
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